BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Castro-Navarro V, Cervera-Taulet E, Navarro-Palop C, Monferrer-Adsuara C, Hernández-Bel L, Montero-Hernández J. Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema. BMC Ophthalmol 2019;19:15. [PMID: 30634940 DOI: 10.1186/s12886-018-1022-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Udaondo P, Adan A, Arias-Barquet L, Ascaso FJ, Cabrera-López F, Castro-Navarro V, Donate-López J, García-Layana A, Lavid FJ, Rodríguez-Maqueda M, Ruiz-Moreno JM. Challenges in Diabetic Macular Edema Management: An Expert Consensus Report. Clin Ophthalmol 2021;15:3183-95. [PMID: 34349495 DOI: 10.2147/OPTH.S320948] [Reference Citation Analysis]
2 Kishore K, Bhat PV, Venkatesh P, Canizela CC. Dexamethasone Intravitreal Implant for the Treatment of Macular Edema and Uveitis: A Comprehensive Narrative Review. OPTH 2022;Volume 16:1019-45. [DOI: 10.2147/opth.s209395] [Reference Citation Analysis]
3 An JH, Kim YC. Difference in the efficacy of intravitreal dexamethasone implant before and after silicone oil removal: A case report. Medicine (Baltimore) 2021;100:e25161. [PMID: 33726001 DOI: 10.1097/MD.0000000000025161] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 De Geronimo D, Giorno P, Scarinci F, Boninfante A, Varano M, Parravano M. Treatment of Diabetic Macular Edema with Multiple Dexamethasone Intravitreal Implants: Evidence from Real-Life Experience. Ophthalmologica 2020;243:413-9. [PMID: 31760387 DOI: 10.1159/000504890] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Mateos-Olivares M, García-Onrubia L, Valentín-Bravo FJ, González-Sarmiento R, Lopez-Galvez M, Pastor JC, Usategui-Martín R, Pastor-Idoate S. Rho-Kinase Inhibitors for the Treatment of Refractory Diabetic Macular Oedema. Cells 2021;10:1683. [PMID: 34359853 DOI: 10.3390/cells10071683] [Reference Citation Analysis]
6 Carnota-méndez P, Méndez-vázquez C, Pérez-gavela C. OCT-Angiography Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Dexamethasone Implant. OPTH 2022;Volume 16:247-63. [DOI: 10.2147/opth.s345947] [Reference Citation Analysis]
7 Liang Y, Yan B, Xie M, Meng Z, Ma J, Ma B, Luo J. One-Month Outcomes of Intravitreal Anti-VEGF vs. Dexamethasone Implant in the Treatment of Diabetic Macular Edema in Vitrectomized Eyes. Front Med 2022;9:895220. [DOI: 10.3389/fmed.2022.895220] [Reference Citation Analysis]
8 Huang YH, Kuo CH, Peng IC, Chang YS, Tseng SH, Conway EM, Wu HL. Recombinant thrombomodulin domain 1 rescues pathological angiogenesis by inhibition of HIF-1α-VEGF pathway. Cell Mol Life Sci 2021;78:7681-92. [PMID: 34705054 DOI: 10.1007/s00018-021-03950-3] [Reference Citation Analysis]
9 Furino C, Niro A, Reibaldi M, Boscia F, Alessio G. Efficacy of Intravitreal Dexamethasone Implant in Different Patterns of Diabetic Macular Edema. J Ophthalmic Vis Res 2020;15:524-30. [PMID: 33133444 DOI: 10.18502/jovr.v15i4.7787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Castro-Navarro V, Monferrer-Adsuara C, Navarro-Palop C, Montero-Hernández J, Cervera-Taulet E. Optical coherence tomography biomarkers in patients with macular edema secondary to retinal vein occlusion treated with dexamethasone implant. BMC Ophthalmol 2022;22:191. [PMID: 35473615 DOI: 10.1186/s12886-022-02415-w] [Reference Citation Analysis]
11 Ruiz-Medrano J, Rodríguez-Leor R, Almazán E, Lugo F, Casado-Lopez E, Arias L, Ruiz-Moreno JM. Results of dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema patients: Early versus late switch. Eur J Ophthalmol 2021;31:1135-45. [PMID: 32493065 DOI: 10.1177/1120672120929960] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Al-Latayfeh M, Abdel Rahman M, Shatnawi R. Outcome of Single Dexamethasone Implant Injection in the Treatment of Persistent Diabetic Macular Edema After Anti-VEGF Treatment: Real-Life Data from a Tertiary Hospital in Jordan. Clin Ophthalmol 2021;15:1285-91. [PMID: 33790536 DOI: 10.2147/OPTH.S303670] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Neves P, Ornelas M, Matias I, Rodrigues J, Santos M, Dutra-Medeiros M, Martins D. Dexamethasone intravitreal implant (Ozurdex) in diabetic macular edema: real-world data versus clinical trials outcomes. Int J Ophthalmol 2021;14:1571-80. [PMID: 34667735 DOI: 10.18240/ijo.2021.10.15] [Reference Citation Analysis]
14 Figueira J, Henriques J, Carneiro Â, Marques-Neves C, Flores R, Castro-Sousa JP, Meireles A, Gomes N, Nascimento J, Amaro M, Silva R. Guidelines for the Management of Center-Involving Diabetic Macular Edema: Treatment Options and Patient Monitorization. Clin Ophthalmol 2021;15:3221-30. [PMID: 34354341 DOI: 10.2147/OPTH.S318026] [Reference Citation Analysis]
15 Wang TY, Chen YH, Chen JT, Liu JT, Wu PY, Chang SY, Lee YW, Su KC, Chen CL. Diabetic Macular Edema Detection Using End-to-End Deep Fusion Model and Anatomical Landmark Visualization on an Edge Computing Device. Front Med (Lausanne) 2022;9:851644. [PMID: 35445051 DOI: 10.3389/fmed.2022.851644] [Reference Citation Analysis]
16 Wallsh J, Luths C, Kil H, Gallemore R. Initial Ten Years of Experience with the Intravitreal Dexamethasone Implant: A Retrospective Chart Review. Clin Ophthalmol 2020;14:3097-108. [PMID: 33116361 DOI: 10.2147/OPTH.S264559] [Reference Citation Analysis]
17 Augustin AJ. Treatment of diabetic macular edema with intravitreal DEX Implant in Germany: Efficacy and safety in naïve and pre-treated patients in clinical practice. European Journal of Ophthalmology. [DOI: 10.1177/11206721221076697] [Reference Citation Analysis]
18 Vadalà M, Trapani VS, Amato M, Bongiovanni G, Alaimo F, Cillino S, Bonfiglio VME. Intraoperative dexamethasone intravitreal implant in diabetic macular edema patients undergoing phacoemulsification: The CataDex study. Eur J Ophthalmol 2021;:11206721211062037. [PMID: 34878320 DOI: 10.1177/11206721211062037] [Reference Citation Analysis]
19 Chawan-Saad J, Wu M, Wu A, Wu L. Corticosteroids for Diabetic Macular Edema. Taiwan J Ophthalmol 2019;9:233-42. [PMID: 31942428 DOI: 10.4103/tjo.tjo_68_19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
20 Alshaikh RA, Waeber C, Ryan KB. Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies. Adv Drug Deliv Rev 2022;187:114342. [PMID: 35569559 DOI: 10.1016/j.addr.2022.114342] [Reference Citation Analysis]
21 Augustin AJ, Becker MD, Hatz K, Kaymak H, Shirlaw A. Assessment of Reinjection Numbers and Intervals for Diabetic Macular Edema Patients Who Received Dexamethasone Intravitreal Implants in Germany and Switzerland. Clin Ophthalmol 2021;15:3957-67. [PMID: 34616140 DOI: 10.2147/OPTH.S315548] [Reference Citation Analysis]
22 Medina-Baena M, Cejudo-Corbalán O, García-Pulido JI, Huertos-Carrillo MJ, Girela-López E. Intravitreal dexamethasone implant in naïve and previously treated patients with diabetic macular edema: a retrospective study. Int J Ophthalmol 2020;13:1597-605. [PMID: 33078111 DOI: 10.18240/ijo.2020.10.14] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Cicinelli MV, Cavalleri M, Lattanzio R, Bandello F. The current role of steroids in diabetic macular edema. Expert Review of Ophthalmology 2020;15:11-26. [DOI: 10.1080/17469899.2020.1729743] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Furino C, Boscia F, Reibaldi M, Alessio G. Intravitreal Therapy for Diabetic Macular Edema: An Update. J Ophthalmol 2021;2021:6654168. [PMID: 33688431 DOI: 10.1155/2021/6654168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Baino F, Kargozar S. Regulation of the Ocular Cell/Tissue Response by Implantable Biomaterials and Drug Delivery Systems. Bioengineering (Basel) 2020;7:E65. [PMID: 32629806 DOI: 10.3390/bioengineering7030065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Udaondo P, Hervas-Ontiveros A, Rosemblatt A, Garcia-Delpech S. Impact of Different Clinical Baseline Characteristics on Intravitreal Dexamethasone Implant Ozurdex® Outcomes. Clin Ophthalmol 2021;15:4153-62. [PMID: 34703201 DOI: 10.2147/OPTH.S336865] [Reference Citation Analysis]
27 Wang JK, Huang TL, Hsu YR, Chang PY. Effect of dexamethasone intravitreal implant for refractory and treatment-naive diabetic macular edema in Taiwanese patients. J Chin Med Assoc 2021;84:326-30. [PMID: 33433135 DOI: 10.1097/JCMA.0000000000000483] [Reference Citation Analysis]
28 Byrne EM, Llorián-Salvador M, Tang M, Margariti A, Chen M, Xu H. IL-17A Damages the Blood-Retinal Barrier through Activating the Janus Kinase 1 Pathway. Biomedicines 2021;9:831. [PMID: 34356895 DOI: 10.3390/biomedicines9070831] [Reference Citation Analysis]
29 Byrne EM, Llorián-Salvador M, Lyons TJ, Chen M, Xu H. Tofacitinib Ameliorates Retinal Vascular Leakage in a Murine Model of Diabetic Retinopathy with Type 2 Diabetes. Int J Mol Sci 2021;22:11876. [PMID: 34769307 DOI: 10.3390/ijms222111876] [Reference Citation Analysis]
30 Karti O, Saatci AO. Place of intravitreal dexamethasone implant in the treatment armamentarium of diabetic macular edema. World J Diabetes 2021; 12(8): 1220-1232 [PMID: 34512888 DOI: 10.4239/wjd.v12.i8.1220] [Reference Citation Analysis]
31 Chhablani J, Wong K, Tan GS, Sudhalkar A, Laude A, Cheung CMG, Zhao P, Uy H, Lim J, Valero S, Ngah NF, Koh A. Diabetic Macular Edema Management in Asian Population: Expert Panel Consensus Guidelines. Asia Pac J Ophthalmol (Phila) 2020;9:426-34. [PMID: 32956188 DOI: 10.1097/APO.0000000000000312] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Mishra SK, Sinha S, Chauhan R, Kumar A. Intravitreal Dexamethasone Implant versus Intravitreal Ranibizumab Injection for Treatment of Non-Proliferative Diabetic Macular Edema: A Prospective, Randomized and Blinded Trial. Curr Drug Deliv 2021;18:825-32. [PMID: 33267762 DOI: 10.2174/1567201817666201202093637] [Reference Citation Analysis]
33 Bikbov MM, Zainullin RM, Kudoyarova KI, Kalanov MR. [Efficacy of intravitreal dexamethasone implant as a starting monotherapy and when switching from an anti-VEGF drug in diabetic macular edema]. Vestn Oftalmol 2021;137:5-11. [PMID: 34965061 DOI: 10.17116/oftalma20211370615] [Reference Citation Analysis]
34 Eandi CM, De Geronimo D, Giannini D, Polito MS, Tosi GM, Neri G, Le Mer Y, Varano M, Parravano M. Baseline SD-OCT characteristics of diabetic macular oedema patterns can predict morphological features and timing of recurrence in patients treated with dexamethasone intravitreal implants. Acta Diabetol 2020;57:867-74. [PMID: 32114643 DOI: 10.1007/s00592-020-01504-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Bux AV, Fortunato F, Barone A, Russo V, Delle Noci N, Iaculli C. Early treatment with dexamethasone intravitreal implants in diabetic macular edema: Naïve versus refractory patients. Eur J Ophthalmol 2021;:11206721211024804. [PMID: 34120496 DOI: 10.1177/11206721211024804] [Reference Citation Analysis]
36 Grzybowski A, Markeviciute A, Zemaitiene R. Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update. J Clin Med 2021;10:5300. [PMID: 34830582 DOI: 10.3390/jcm10225300] [Reference Citation Analysis]